Peptide therapy is one of the fastest-growing segments in functional and regenerative medicine. Patients are asking for it. Practitioners are adding it. Wellness operators who move now get the market before it becomes table stakes.
This guide is for the practitioner or operator who has decided to add peptide therapy and wants a clear, actionable path to doing it right.
What “Adding Peptide Therapy” Actually Means
Before getting into the how, it helps to define what you are actually adding.
A peptide therapy program is a physician-supervised protocol where a patient is evaluated, a prescription peptide is prescribed, and the compound is compounded by a licensed pharmacy and shipped directly to the patient. The patient self-administers (typically subcutaneous injection) and receives ongoing clinical oversight through the program.
You can build this from scratch, or you can use a platform that has already built the infrastructure.
From scratch means: hiring or contracting licensed prescribers in each state, contracting with a 503A compounding pharmacy, building HIPAA-compliant intake and patient management technology, configuring subscription billing, creating consent documentation, and managing ongoing compliance. Timeline: 6 to 18 months. Cost: $50,000 to $200,000+.
On a platform means: connecting your business to an existing prescriber network, pharmacy, technology stack, and compliance infrastructure. You own the patient relationship and the marketing. The platform handles the rest. Timeline: 1 to 3 weeks. Cost: setup fee plus revenue share per patient.
Most operators should start with the platform model. The economics are favorable, the regulatory risk is managed, and time to revenue is weeks, not months.
Step 1: Define Your Patient Audience
The peptides you launch should match the patients you already have access to.
If you work with active adults, athletes, or fitness clients: CJC-1295/Ipamorelin (growth hormone optimization) and BPC-157 (recovery) are your entry points. These patients are already investing in performance and are comfortable with evidence-adjacent protocols.
If you run a weight loss, metabolic, or longevity program: Semaglutide or tirzepatide for weight loss. CJC-1295/Ipamorelin for patients focused on body composition and anti-aging. BPC-157 as a gut health add-on.
If you treat musculoskeletal patients (chiropractors, sports medicine, orthopedics): BPC-157 is the obvious starting point. Patients with soft tissue injuries, post-surgical recovery, or chronic pain are well-matched to BPC-157’s mechanism.
If you run a med spa or aesthetics practice: BPC-157, GHK-Cu, and CJC-1295/Ipamorelin all connect to aesthetics outcomes. Skin quality, wound healing, collagen synthesis. Your patients are already paying for appearance optimization.
If you are a functional medicine or hormone optimization provider: You likely have patients who are already asking about peptides. CJC-1295/Ipamorelin as a GH optimization add-on to TRT programs is the most common entry point.
Starting with one program laser-targeted at your core audience is more effective than launching a full menu. You can expand after your first cohort demonstrates the model.
Step 2: Understand the Regulatory Basics
Peptide therapy occupies a specific regulatory context. Knowing the basics protects you and helps you market accurately.
Compounded vs. FDA-Approved
Most therapeutic peptides are compounded, not FDA-approved for the indications they are used for. Compounding pharmacies operating under 503A rules can compound these peptides with a valid prescription for individual patients. This is legal and standard practice. It is different from purchasing FDA-approved drugs.
FDA’s Bulk Drug Substance Review
The FDA is reviewing peptides used in compounding through its bulk drug substance review process. Some peptides (including semaglutide-related compounds) have faced restrictions. Others remain on the review list with no adverse action. Understanding this landscape is important if you are building a program that depends on specific compounds.
Off-Label and Informed Consent
All peptide use is off-label. Patients should receive informed consent documentation that clearly explains this, states the nature of the evidence base, and confirms they understand the treatment is not FDA-approved for this indication. A reputable platform partner provides this documentation.
What You Cannot Say
Avoid claiming peptides treat, cure, or prevent specific diseases unless the compound has FDA approval for that indication. Do not guarantee results. Do not make claims that go beyond the available evidence. These rules apply to websites, social media, email, and any other marketing channel.
A good rule of thumb: describe outcomes patients are likely to experience, the mechanism of action, and the program structure. Let patients draw their own conclusions about whether it is right for them.
Step 3: Choose Your Platform or Infrastructure
If you are using a turnkey platform, evaluate on these criteria:
Prescriber coverage: Do they have licensed providers in all states where your patients are? Telehealth prescribing rules vary by state; some require synchronous video consultations, others allow asynchronous intake.
Pharmacy relationships: Do they work with PCAB-accredited 503A pharmacies? Accreditation is the clearest proxy for quality control in compounding.
Technology: Does the platform provide patient intake, HIPAA-compliant messaging, prescription management, and subscription billing? Or do you need to patch multiple systems together?
Compliance support: Do they provide marketing guidelines, consent documentation, and legal review? Or are you on your own?
Revenue structure: Revenue share, per-patient fee, or markup? Model the economics at 50 patients and 150 patients to understand which structure works for your volume.
White-label capability: Can your patients interact with your brand or does everything point to the platform’s brand?
Karpa Health is built for non-medical operators and practitioners who want to launch a branded peptide program without building infrastructure. The platform provides prescribers, pharmacy, technology, and compliance support under your brand.
Step 4: Set Up Your Program
Once you have chosen a platform, the setup involves:
Define your program menu. One to three peptide programs to start. Describe each clearly: what it is, who it is for, what patients can expect, and at what price point.
Set your pricing. Peptide programs typically run $150 to $400 per month depending on the compound, dose, and program services included. Price to support sustainable gross margins. On a turnkey platform, your margins are the spread between your patient price and the platform cost per patient. A standard BPC-157 program at $199/month with $60 platform costs = $139 gross profit per patient per month.
Develop your intake flow. What questions do patients answer before scheduling a consultation? What information do prescribers need to make a prescribing decision? Good intake design reduces consultation time and improves prescribing efficiency.
Configure your billing. Monthly subscription is standard. Decide whether you require a minimum commitment (3 months is common and justified given program timelines) or allow month-to-month.
Prepare your marketing materials. Website copy, landing page, email sequence for inquiries, social content. Stay within compliance guidelines. Your platform partner should review materials before launch.
Step 5: Acquire Your First Patients
Your first patients should come from your existing audience. This is faster, cheaper, and produces stronger outcomes than cold acquisition.
For practitioners: Identify patients who have raised relevant concerns in consultations (fatigue, body composition, recovery, aging, joint pain). A brief announcement to your existing patient list will generate inquiries from people who were already interested but did not know you offered this.
For health coaches and trainers: Your current clients are your first market. A direct conversation (“I am now offering a physician-supervised peptide recovery program for clients who want faster results”) converts much more efficiently than any paid ad.
For gym owners and studios: Post-purchase sequences for existing members, signage, a brief intro in classes or training sessions. High-intent buyers are already in your environment.
For influencers and content creators: A dedicated post explaining what you are offering, why you chose this program, and what patients can expect. Personal experience content converts exceptionally well in this category.
Paid acquisition works once you have validated your program with organic enrollments. Start paid after you have documented results, can articulate your offer clearly, and have a landing page that converts. Do not start with paid ads before you have patient evidence.
Step 6: Retain and Grow
Retention is where the economics of peptide therapy become exceptional.
Patients who see results stay. The key to retention is:
Outcome monitoring. Track IGF-1 (for GH programs), symptoms at 4 and 12 weeks, and functional outcomes patients care about. Patients who see objective improvement in labs or measurable outcomes stay.
Consistent communication. Monthly check-ins, educational content about the program, updates when protocols are adjusted. Patients who feel managed stay. Patients who feel abandoned churn.
Upsell pathways. Patients on one program are your best prospects for adding a second. BPC-157 patients with body composition goals are natural CJC-1295/Ipamorelin candidates. CJC-1295/Ipamorelin patients who ask about testosterone are natural TRT candidates.
Referral activation. Peptide therapy patients who see results tell people. A simple referral mechanism (discount for both referrer and new patient) converts word-of-mouth into systematic growth.
What to Expect in the First 90 Days
| Milestone | Timeline |
|---|---|
| Platform setup and configuration | Week 1 |
| Marketing materials live | Week 1-2 |
| First consultations booked | Week 2 |
| First prescriptions written | Week 2-3 |
| First batch of 10-20 active patients | Week 4-6 |
| Initial outcome check-ins | Week 6-8 |
| First retention data | Month 3 |
| First referral patients | Month 2-3 |
Operators with existing audiences of 1,000 or more reach 50 active patients within 60 to 90 days. Operators starting from zero take longer but benefit from the compounding effect of patient referrals over time.
The Bottom Line
Adding peptide therapy is straightforward when you have the right infrastructure. The clinical demand is there. The patient willingness to pay is there. The regulatory framework, while evolving, supports compliant programs today.
The operators who are winning in this space launched, learned, and iterated. They did not wait for perfect information.
See how Karpa Health supports operators at every stage of building a peptide therapy program.
Ready to understand specific programs? Read the BPC-157 prescription guide or the CJC-1295/Ipamorelin program guide.
Book a call with Karpa Health if you want help structuring the right program.
